NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell (ASC) technology, announced today that the company has retained the services of Bio Medical Research Design (BRD) headed by Dr. Moshe Neuman to consult BrainStorm’s regulatory team in its preparations for clinical trials of ALS patients in Israel.
